The text provides comprehensive financial information for Johnson & Johnson and its subsidiaries, presenting details on their balance sheets, earnings, comprehensive income, equity statements, and cash flows for the fiscal first quarter ended April 2, 2023. It includes information on assets, liabilities, earnings per share, and cash flows from operating, investing, and financing activities in millions of dollars. Furthermore, the company discusses recent accounting standards adopted and potential impacts on its financial statements, as well as segmented data, legal proceedings, acquisitions, divestitures, and recent acquisitions such as Abiomed. It also delves into ongoing legal issues, including personal injury claims and court rulings related to talc use, settlements, and bankruptcy filings.
The text provided discusses the Management's Discussion and Analysis of Financial Condition and Results of Operations for a corporation. It details the performance of various segments, such as Sales to Customers, Consumer Health, Pharmaceutical, and MedTech. It includes discussions on sales growth, operational performance, major franchises, sales by business segments, acquisitions/divestitures, and initiatives like separating the Consumer Health business. Moreover, it gives insights into earnings, expenses, taxes, interest income/expense, R&D expenses, restructuring efforts, and liquidity/capital resources. The document also mentions new accounting pronouncements, economic and market factors (including the Russia-Ukraine war impact), cash flows, dividends, and the company's response to global challenges and changing tax laws. The company's financial status, including cash levels, borrowings, debts, and future plans like an IPO launch, share repurchases program, dividends, and reactive strategies in volatile markets, have been detailed thoroughly.
The text provided discusses the absence of any significant alterations in the company's evaluation of its market risk sensitivity, since the presentation in Item 7A of its Annual Report on Form 10-K for the fiscal year ended January 1, 2023.
The text describes the evaluation of the effectiveness of a company's disclosure controls and procedures at the end of the reporting period. The controls are in place to ensure required information is accurately recorded, processed, and reported according to SEC rules and timelines. Chief Executive Officer and Chief Financial Officer reviewed and confirmed the effectiveness of these controls. Additionally, there were no significant changes in internal control over financial reporting during the period. The company continues to monitor and assess the effectiveness of its controls and procedures.
The text provided references a specific item concerning legal proceedings within a document. The content concerning legal proceedings can be found in Note 11 of Part I, Item 1, Financial Statements (unaudited) – Notes to Consolidated Financial Statements.
Please provide the text parts for me to summarize.
The Company's Board of Directors approved a share repurchase program on September 14, 2022, allowing the purchase of up to $5.0 billion of Common Stock. Share repurchases were made on the open market or through negotiated transactions, and the program was completed in the first quarter of 2023. Over the course of that quarter, the Company repurchased 21,647,317 shares of Common Stock, with 15,134,442 being part of the publicly announced repurchase plan. In total, 30,546,218 shares were purchased by April 2, 2023, with a total value of $5.0 billion since the program's inception.
I apologize, but it seems like you have not sent any parts of the text yet. Could you please provide the text that needs to be summarized?
I am ready to receive the text parts for summarization. Please go ahead and provide them.
I understand. Please go ahead and provide all the parts of the text for summarization.
The text provided includes a list of exhibits related to stock awards and certifications, as well as signatures from Johnson & Johnson's executive officers, such as the Chief Financial Officer and Controller. The exhibits include agreements for Performance Share Unit Awards, Restricted Share Unit Awards, and Nonqualified Stock Option Awards. There are also certifications under the Sarbanes-Oxley Act of 2002 and XBRL tags embedded within the Inline XBRL document. The document is signed by the company's executives, such as the Executive Vice President and the Controller, on April 28, 2023.
